论文部分内容阅读
目的探讨血清胰岛素样生长因子结合蛋白-2(IGFBP-2)水平与肝细胞癌的关系及其在肝癌的诊断、治疗中潜在价值。方法采用酶联免疫吸附试验ELISA法测定肝细胞癌组(54例)血清IGFBP-2、IGFBP-3、AFP、IGF-1、IGF-2、GH水平与肝硬化组(20例)和健康对照组(32例)结果对照比较。结果肝细胞癌组血清IGFBP-2水平明显高于肝硬化组和健康对照组(t=4.63,P<0.05,t=3.73,P<0.01),肝硬化组和健康对照组比较差异无统计学意义。肝癌切除术后4周IGFBP-2水平明显下降,与术前相比差异有统计学意义(t=3.52,P<0.05)。肝细胞癌组GH、IGF-1、IGF-2、IGFBP-3水平与肝硬化组对比差异无统计学意义。相关性分析显示肝细胞癌组IGFBP-2与AFP水平呈正相关(r=0.51,P<0.05),与GH、IGF-1、IGF-2、IGFBP-3无相关性。结论肝细胞癌患者IGFBP-2水平的异常增高可能与肝癌细胞合成释放增加有关。与AFP结合使用血清IGFBP-2检测可成为肝癌筛查、监测的有效手段。
Objective To investigate the relationship between the serum level of insulin-like growth factor binding protein-2 (IGFBP-2) and hepatocellular carcinoma (HCC) and its potential value in the diagnosis and treatment of liver cancer. Methods Serum levels of IGFBP-2, IGFBP-3, AFP, IGF-1, IGF-2, and IGF-2 in patients with hepatocellular carcinoma (HCC) were measured by enzyme linked immunosorbent assay (ELISA) Group (32 cases) comparison of the results of the control. Results The serum level of IGFBP-2 in hepatocellular carcinoma was significantly higher than that in cirrhosis and healthy controls (t = 4.63, P <0.05, t = 3.73, P <0.01). There was no significant difference between the cirrhosis and healthy controls significance. The level of IGFBP-2 significantly decreased 4 weeks after hepatectomy, which was significantly different from that before operation (t = 3.52, P <0.05). There were no significant differences in the levels of GH, IGF-1, IGF-2 and IGFBP-3 between hepatocellular carcinoma and cirrhosis patients. Correlation analysis showed that there was a positive correlation between IGFBP-2 and AFP in hepatocellular carcinoma (r = 0.51, P <0.05), but not with GH, IGF-1, IGF-2 and IGFBP-3. Conclusion The abnormal increase of IGFBP-2 in patients with hepatocellular carcinoma may be related to the increased release of hepatocellular carcinoma cells. Combined with AFP serum IGFBP-2 test can be an effective screening and monitoring of liver cancer.